GENFIT/GNFT

$3.58

-2.17%
-
1D1W1MYTD1YMAX

About GENFIT

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Ticker

GNFT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jean-Francois Mouney

Employees

159

Headquarters

Loos, France

GENFIT Metrics

BasicAdvanced
$177.43M
Market cap
-
P/E ratio
-$0.62
EPS
1.07
Beta
-
Dividend rate
$177.43M
1.07123
$4.75
$2.89
12.49K
2.94
2.939
91.615
103.269
-7.78%
-14.84%
-35.57%
-18.55%
4.367
2.467
8.688
43.7%
-21.75%
70.09%

GENFIT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-35.08% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€22.8M
49.02%
Net income
€-8M
-61.54%
Profit margin
-35.08%
-74.19%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for GENFIT stock?

GENFIT (GNFT) has a market cap of $177.43M as of April 14, 2024.

What is the P/E ratio for GENFIT stock?

The price to earnings (P/E) ratio for GENFIT (GNFT) stock is 0 as of April 14, 2024.

Does GENFIT stock pay dividends?

No, GENFIT (GNFT) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next GENFIT dividend payment date?

GENFIT (GNFT) stock does not pay dividends to its shareholders.

What is the beta indicator for GENFIT?

GENFIT (GNFT) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the GENFIT stock price target?

The target price for GENFIT (GNFT) stock is $, which is 100% below the current price of $3.58. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell GENFIT stock

Buy or sell GENFIT stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing